markets · · newsfilecorp.com
Thiogenesis Announces FDA Clearance of IND for Nephropathic Cystinosis
Investigator-initiated study led by Dr. Larry Greenbaum of Emory University to evaluate once-daily oral powder TTI-0102, designed to improve adherence San Diego, California--(Newsfile Corp. - October 22, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company") today announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application for TTI-0102 in nephropathic cystinosis. On October 16, 2026, the FDA issued a "Study May Proceed" letter for IND 184780.
Investigator-initiated study led by Dr. Larry Greenbaum of Emory University to evaluate once-daily oral powder TTI-0102, designed to improve adherence San Diego, California--(Newsfile Corp. - October 22, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company") today announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application for TTI-0102 in nephropathic cystinosis. On October 16, 2026, the FDA issued a "Study May Proceed" letter for IND 184780.
- #TTI